tbuckley/cabot-search huggingface dataset:
Novel Artificial Neural Network for Early Detection of Prostate Cancer
Authors: B. Djavan
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Two artificial neural networks (ANN) for the early detection of prostate cancer in men with total prostate-specific antigen (PSA) levels from 2.5 to 4 ng/mL and from 4 to 10 ng/mL were prospectively developed. The predictive accuracy of the ANN was compared with that obtained by use of conventional statistical analysis of standard PSA parameters. PATIENTS AND METHODS: Consecutive men with a serum total PSA level between 4 and 10 ng/mL (n = 974) and between 2.5 and 4 ng/mL (n = 272) were analyzed. A separate ANN model was developed for each group of patients. Analyses were performed to determine the presence of prostate cancer. RESULTS: The area under the receiver operator characteristic (ROC) curve (AUC) was 87.6% and 91.3% for the 2.5 to 4 ng/mL and 4 to 10 ng/mL ANN models, respectively. For the latter model, the AUC generated by the ANN was significantly higher than that produced by the single variables of total PSA, percentage of free PSA, PSA density of the transition zone (TZ), and TZ volume (P < .01), but not significantly higher compared with multivariate analysis. For the 2.5 to 4 ng/mL model, the AUC of the ANN ROC curve was significantly higher than the AUCs for percentage of free PSA (P = .0239), PSA-TZ (P = .0204), and PSA density and total prostate volume (P < .01 for both). CONCLUSION: The predictive accuracy of the ANN was superior to that of conventional PSA parameters. ANN models might change the way patients referred for early prostate cancer detection are counseled regarding the need for prostate biopsy.
Computers for the Practicing Physician: Update 1986
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Computers for the Practicing Physician: Update 1986 Get access JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Page 1339, https://doi.org/10.1093/jnci/76.6.1339-c Published: 01 June 1986
Induction of immune tolerance to factor VIII: a plea for caution
Authors: H. R. Roberts
Journal: JAMA (1988)

Anti—factor VIII antibodies (inhibitors) occur in about 15% of severely affected hemophilic patients.<sup>1</sup>This is a serious complication that precludes treatment with conventional doses of factor VIII. Factor VIII inhibitors fall into two broad categories: (1) "low" response inhibitors, ie, antibodies that remain at a titer of less than 10 Bethesda units (BU) per milliliter even after challenge with factor VIII; and (2) "high" response inhibitors, ie, antibodies that demonstrate an anamnestic increase in titer to levels greater than 10 BU/mL and quite often to values in excess of 100 BU/mL after challenge with factor VIII. Bleeding episodes in individuals with high-response inhibitors are extremely difficult to manage, and therapeutic options are limited. Thus, treatment that will reduce or eradicate anti—factor VIII antibodies represents a major therapeutic advance in the treatment of hemophilia. See also p 65. In Bonn, West Germany, during the 1970s, Brackmann and Egli<sup>1</sup>developed
Clinical use of viable frozen human skin
Authors: R. B. Berggren
Journal: JAMA (1965)

After a method for the successful freezing and storing of viable skin was developed in the laboratory, it was applied to human skin grafts. Split-thickness skin was prepared by soaking in 10% dimethyl sulfoxide (DMSO) and frozen in dry ice. It was then stored at liquid nitrogen temperatures (—196 C) for periods up to 608 days. The grafts were used in various clinical situations. The success of the grafts was directly related to the status of the recipient bed and showed no relation to the time of storage. The grafts have been used in 26 cases as autografts and 12 cases as homografts.
Lupoid Hepatitis: Comparison of 22 Cases with Other Types of Chronic Liver Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical Practice of the Lahey Clinic, Boston, Massachusetts
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: <i>Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis</i>
Journal: Gut (2018)

The colour keys in the figure 4 legend have been corrected to read:(A) Score of the pancreatic biomarker signature identified in the training set and applied on the test set.Non-pancreatic controls in grey (n=80), chronic pancreatitis in green (n=80) and pancreatic cancer in magenta (n=79).Box plots give median, upper quartile and lower quartile by the box and the upper adjacent and lower adjacent values by the whiskers.The upper adjacent value is the largest observation that is less than or equal to the upper inner fence, which is the third quartile plus 1.5-fold IQR.The lower adjacent value gives the corresponding value for downregulation.The diagnostic cut-off of the pancreatic biomarker score was set to ≥0.384.(B) Scatter plot for graphical representation of the biomarker signature score.Classifiers are the biomarker signature generated in the training set and presented here for the test set.Y-axis score of biomarker signature with the cut-off of ≥0.384 and CA19-9 on the X axis with the cut-off ≥37 U/mL.Chronic pancreatitis in green circles (n=80) and pancreatic cancer in magenta circles (n=79).Numbers give subjects that benefit from the biomarker signature and all numbers in the respective area of the plot.
Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration
Authors: Nicole A. Morin, Patrick W. Oakes, Young-Min Hyun, Dooyoung Lee, Y. Eugene Chin, Michael R. King, Timothy A. Springer, Motomu Shimaoka, Jay X. Tang, Jonathan S. Reichner, Minsoo Kim
Journal: The Journal of Experimental Medicine (2008)
Structure and Function of Cyclic Nucleotide-Gated Channels
Authors: W. N. Zagotta
Journal: Annual Review of Neuroscience (1996)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
The Unborn
Authors: Hans O. Tiefel
Journal: JAMA (1978)

RECENT controversies about abortion, fetal experimentation, and the nontreatment of seriously diseased newborns raise a recurrent set of underlying questions: Are the unborn human beings? What is a human being and what is its value? What are our responsibilities toward beings whose human status is in doubt? This essay analyzes the interconnections between these questions and states as well as defends one of two alternative responses to them. One is never quite sure of the right sequence of these questions. The more traditional order, and the one followed here, is to begin with human status and to move to responsibilities or rights. But it is probably true that our definitions of "human being"—or even our choice of alternative basic terms such as "person" or "unborn child"—are deliberate and will allow us to support whatever moral responsibilities we wish to advocate. Yet, whether we start with asking who is a human
Physicians and Patient Spirituality
Authors: John Graner
Journal: Annals of Internal Medicine (2001)

Letters7 August 2001Physicians and Patient SpiritualityJohn Graner, MDJohn Graner, MDMayo Clinic; Rochester, MN 55905 (Graner)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-3-200108070-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:It is perfectly valid to base one's public conduct on religious principles. Thus, I don't object to Dr. Bodey allowing his religious beliefs to dictate his actions in broad ethical terms, as long as he does not impose his particular belief structure on others. This is obviously a separate issue from the display of religious icons in a clinic office. To the extent that this office is a site of medical care for those of all faiths and creeds, it represents a segment of the secular, public space. As opposed to many other world cultures, secularization, that is, ...Reference1. Arendt H. Between Past and Future. New York: Penguin Books; 1987:41-90. Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic; Rochester, MN 55905 (Graner) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPhysicians and Patient Spirituality John Graner Physicians and Patient Spirituality Gerald P. Bodey Physicians and Patient Spirituality Susan B. LeGrand Physicians and Patient Spirituality John Graner Physicians and Patient Spirituality Susan B. LeGrand Physicians and Patient Spirituality Fritz Baumgartner Metrics Cited ByPhysicians and Patient SpiritualityFritz Baumgartner, MDPhysicians and Patient SpiritualitySusan B. LeGrand, MD 7 August 2001Volume 135, Issue 3Page: 220KeywordsSports ePublished: 7 August 2001 Issue Published: 7 August 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Honeycomb lung (interstitial fibrosis)
Authors: J. C. Reed
Journal: JAMA (1975)

<h3>Common</h3> [Cystic bronchiectasis] Histiocytosis X (especially eosinophilic granuloma) Idiopathic interstitial fibrosis (Hamman-Rich ) Pneumoconiosis Sarcoidosis <h3>Uncommon</h3> Amyloidosis Chemical inhalation (late stage) Desquamative interstitial pneumonitis (DIP) Drug sensitivity, chronic or recurrent (eg, nitrofurantoin, hexamethonium, busulfan) Gaucher disease Lipoid pneumonia (eg, mineral oil aspiration) [Lymphangiomyomatosis] Oxygen toxicity [Mucoviscidosis] Neurofibromatosis Rheumatoid lung Scleroderma; dermatomyositis Sensitivity pneumonitis, recurrent (eg, farmer's lung, bagassosis) Tuberous sclerosis (Entities in brackets can be confused roentgenographically with true honeycomb lung. ) <h3>Diagnosis</h3> Eosinophilic granuloma. <h3>COMMENTS</h3> In analyzing this Gamut, a number of the possibilities offered, such as chemical inhalation, rheumatoid lung, and scleroderma are excluded by the lack of specific clinical information. Of the common causes, cystic bronchiectasis tends to show fluid in the cysts and to expand on inspiration; pneumoconiotics have a history of dust exposure. Therefore, idiopathic interstitial fibrosis (the
Vaccination in pediatric emergency departments
Authors: C. M. Olson
Journal: JAMA (1993)

Many characteristics of inner-city pediatric emergency departments (EDs) make them seem well suited to administer vaccines. They avoid the need for appointments and the inconvenient hours cited as impediments to vaccination,<sup>1</sup>and they have the equipment, drugs, and personnel needed to deal with severe adverse reactions.<sup>2</sup>In addition, a large proportion of the children seen in inner-city EDs are underimmunized. Two studies reported in this issue ofTHE JOURNALgive examples. In one,<sup>3</sup>36% of children 3 months to 5.5 years old had not received all age-appropriate immunizations according to their accompanying adults, and 47% had not received all immunizations according to their clinic records. In the other study,<sup>4</sup>18% to 29% of children 6 months to 5 years old needed measles vaccination and had no contraindication to receiving one during a measles epidemic. At the same time, these two articles<sup>3,4</sup>highlight problems with the
Application of the Virtual Cancer Patient Engine (VCPE) for improving oncological treatment desig
Authors: Z. Agur, L. Arakelyan, G. Belilty, N. Dahan, H. Harpak, Y. Kogan, Y. Merbl, A. Rabinovich, M. Shoham, I. Ziv
Journal: Journal of Clinical Oncology (2004)

692 Background Physicians are limited in their capacity to individually patient-tailor the safest and most efficient treatments in terms of drug and schedule choices, partly due to individual response variability. We have developed a computerized mathematical tool (VCPE), which was successful in retrieving In Vivo experiments. In the present work we retrospectively validated the tool and studied its ability to suggest improved Doxorubicin treatments. Methods VCPE, a combined platform of computerized mathematical models, simulates short/long-term cellular dynamics of specific patients undergoing drug therapy. It integrates patient hematopoiesis and tumor progression, from avascular growth through angiogenesis and metastasis, with a pharmacokinetics model accounting for drug Absorption, Diffusion, Metabolism and Excretion, and a pharmacodynamics model quantifying drug effects on several target tissues. Results VCPE retrospectively retrieved results of chemotherapy and biologic drug treatments: Tumor Growth-Human breast cancer xenografted in mice, providing analysis of tumor vessel characteristics for improved selection of individual treatment protocols Drug Efficacy-Doxorubicin/Paclitaxel effects on breast cancer -In Vitro response of breast tumor metastases to Doxorubicin Drug Toxicity-Neutrophil counts in Doxorubicin+G-CSF treated breast cancer patients -Thrombocytopenia of patients responding to Doxorubicin combination. Subsequently, the outcomes of yet untested treatment protocols were predicted. Thus it was shown that Doxorubicin therapy, effective for slow growing tumors, can be ineffective for fast growing tumors. An improved Doxorubicin protocol for aggressive breast cancer tumors is suggested. Conclusions VCPE simulates anticancer drug efficacy and toxicity, predicting treatment outcomes for individual patients and offering per-case choice of drug, drug combinations and schedules to achieve clinically desired end-points. Patient information, eg., histopathology, previous treatment responses, blood tests, genetic profile, etc., can be incorporated for fine-tuning results precision. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Optimata Optimata
Highlights
Journal: JAMA Dermatology (2018)

Dermatology Consultation for Presumed Cellulitis 529Each year, cellulitis leads to 650 000 hospital admissions.The literature has reported a high misdiagnosis rate for cellulitis, resulting in unnecessary antibiotic use and health care cost.In this randomized clinical trial, Ko et al demonstrate that early dermatologic consultation can improve outcomes in patients with suspected cellulitis by identifying alternate diagnoses, treating modifiable risk factors, and decreasing the duration of antibiotic treatment.Fastidious antibiotic stewardship not only limits adverse events on an individual level, but also prevents drug resistance at a community level.
TOPICS OF THE WEEK.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Glucose-Insulin-Potassium Solution and Hypoglycemia
Authors: Lynda S. Koehler, David R. Brown, Edward A. Norfleet
Journal: JAMA (1978)

<h3>To the Editor.—</h3> Glucose-insulin-potassium (GIK) solution was originally introduced as a possible means of preservation of the ischemic myocardium.<sup>1</sup>In this institution GIK solution has been used preoperatively for 12 hours in adult patients undergoing coronary-artery-bypass graft procedures to protect the ischemic myocardium before and during the institution of cardiopulmonary bypass. In recent months we have begun use of the membrane oxygenator and have used crystaloid pump prime (lactated Ringer's solution to albumin in the ratio 1 liter to 25 g) instead of the partial blood prime that had been used with the bubble oxygenator. When the patient arrived in the operating room, the administration of GIK solution was discontinued. Intravenous fluid administration was continued with 1 liter of 5% dextrose in 0.2 normal saline, followed by lactated Ringer's solution until cardiopulmonary bypass began. We obtained blood glucose levels before starting the bypass and at one-half hour after bypass
Asthma: Its Diagnosis and Treatment.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatology Highlights
Authors: Hira Hanif, Mukarram Jamat Ali, Hao Wei Chen, Daryl T.Y. Lau, Gopanandan Parthasarathy, Robert E. Schwartz, Adebowale O. Bamidele, Nabeel A. Wahid, Russell Rosenblatt, David M. Salerno, Robert S. Brown, Adam Buckholz, Cesar Taborda, Joel Wedd, Alyson Kaplan, Brett E. Fortune, Nidhi Jalan‐Sakrikar
Journal: Hepatology (2021)

Hanif, Hira; Ali, Mukarram Jamat; Chen, Hao Wei; Lau, Daryl T.Y.; Parthasarathy, Gopanandan; Schwartz, Robert E.; Bamidele, Adebowale O.; Wahid, Nabeel A.; Rosenblatt, Russell; Salerno, David M.; Brown, Robert S. Jr.; Buckholz, Adam; Taborda, Cesar; Wedd, Joel; Kaplan, Alyson; Fortune, Brett E.; Jalan‐Sakrikar, Nidhi Author Information
Abstract 11135: Missed Opportunities! End-Of-Life Discussions and Implantable Cardioverter Defibrillator Recipients
Authors: Jennifer Miller, Ingela Thylen, Martha J Biddle, Alison L Bailey, Muna H Hammash, Debra K Moser
Journal: Circulation (2015)

Introduction: Guidelines for device based therapy of cardiac rhythm abnormalities were updated by the ACC/AHA/HRS in 2008 to include discussions beginning at the time of implantation with implantable cardioverter defibrillator (ICD) recipients regarding end-of-life (EOL) choices and withdrawal of defibrillation therapy. The level of adherence to this guideline from the patients’ perspective is unknown. Methods: The purpose of this study was to determine (1) ICD patients’ perspectives about discussions held with their providers focused on EOL choices regarding the withdrawal of defibrillation therapy and (2) ICD recipients’ level of knowledge regarding ICD function at EOL. ICD recipients from outpatient cardiology clinics associated with an academic health center, a community hospital, or a suburban hospital located in Central Kentucky completed the EOL-ICD questionnaire. The EOL-ICD measures three domains: experiences of EOL issues, attitudes about EOL discussions and actions, and knowledge of the ICD in relation to EOL issues. This instrument is valid and reliable in the ICD population. Results: Of the 115 ICD recipients (mean age = 63 yrs., 22% non-white, 24% non-partnered, with a mean educational level = 13.6 yrs., a mean duration of therapy = 5yrs., and 34% reporting one or more ICD shocks) 71% reported that they have never had discussions with their health care provider regarding what withdrawal of defibrillation therapy implies. A total of 44% believed that turning off the ICD shocks was the same as active euthanasia and that to disable defibrillation therapy required surgical intervention; 43% believed that once defibrillation was disabled it could not be enabled again; and 24% of recipients believed that the heart would stop beating due to the withdrawal of defibrillation therapy. Conclusion: Adherence to the guidelines regarding EOL discussions with ICD recipients was minimal from the patients' perspective. Despite national and international guideline recommendations to discuss EOL issues with ICD recipients beginning at implant, most patients report not having these discussions and many hold alarming misperceptions that could interfere with optimal EOL care.